Anheuser Busch Inbev NV ADR (BUD)vsPfizer Inc (PFE)
BUD
Anheuser Busch Inbev NV ADR
$68.06
-0.71%
CONSUMER DEFENSIVE · Cap: $133.23B
PFE
Pfizer Inc
$27.28
+1.19%
HEALTHCARE · Cap: $153.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 5% more annual revenue ($62.58B vs $59.32B). PFE leads profitability with a 12.4% profit margin vs 11.5%. BUD appears more attractively valued with a PEG of 1.60. BUD earns a higher WallStSmart Score of 61/100 (C+).
BUD
Buy61
out of 100
Grade: C+
PFE
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$158.65
Current Price
$68.06
$90.59 discount
Margin of Safety
-194.9%
Fair Value
$9.25
Current Price
$27.28
$18.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 63.3% YoY
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 24.9%
Generating 9.9B in free cash flow
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Generating 4.5B in free cash flow
Areas to Watch
Expensive relative to growth rate
4.8% revenue growth
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.2%
Earnings declined 21.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BUD
The strongest argument for BUD centers on EPS Growth, Market Cap, Price/Book.
Bull Case : PFE
The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.
Bear Case : BUD
The primary concerns for BUD are PEG Ratio, Revenue Growth.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
BUD profiles as a value stock while PFE is a declining play — different risk/reward profiles.
BUD carries more volatility with a beta of 0.73 — expect wider price swings.
BUD is growing revenue faster at 4.8% — sustainability is the question.
BUD generates stronger free cash flow (9.9B), providing more financial flexibility.
Bottom Line
BUD scores higher overall (61/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anheuser Busch Inbev NV ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?